Is It Possible to Prevent Ovarian Hyperstimulation Syndrome by Gonadotropin-Releasing Hormone Agonist Triggering and Modified Luteal Support in Patients With Polycystic Ovarian Morphology?
Autor: | Dilek Incesu, Necati Ozcimen, Mert Küçük, Ali Sami Gurbuz, Sezen Bozkurt Koseoglu, Rüya Deveer |
---|---|
Rok vydání: | 2016 |
Předmět: |
“Freeze-all” policy
0301 basic medicine Agonist endocrine system medicine.medical_specialty medicine.drug_class Ovarian hyperstimulation syndrome Human chorionic gonadotropin Andrology 03 medical and health sciences 0302 clinical medicine Internal medicine Gonadotropin-releasing hormone agonist medicine GnRH agonist Luteal support 030219 obstetrics & reproductive medicine business.industry General Medicine medicine.disease Polycystic ovary Embryo transfer 030104 developmental biology Endocrinology OHSS Original Article GnRH agonist trigger hCG business hormones hormone substitutes and hormone antagonists Hormone |
Zdroj: | Journal of Clinical Medicine Research |
ISSN: | 1918-3011 1918-3003 |
DOI: | 10.14740/jocmr2500w |
Popis: | Background: Gonadotropin-releasing hormone (GnRH) agonist triggering plus 1,500 IU human chorionic gonadotropin (hCG) supplementation protocol was previously claimed effective in reducing the ovarian hyperstimulation syndrome (OHSS) incidence in high responders. Methods: This retrospective study included women with polycystic ovarian (PCO) morphology who were at high risk of OHSS and were given the GnRH agonist trigger plus hCG luteal support protocol in a single center. Results: The mean peak estradiol level was 5,336 ± 2,341 (1,187 - 19,746) pg/mL. The mean number of follicles > 12 mm on the day of trigger was 22 ± 7 (9 - 51). A total of 88 cycles were undertaken. Sixty-three (71.5%) women underwent fresh embryo transfer. Fresh embryo transfer was canceled in 21 (23.8%) and embryo transfer was canceled in four (4.5%) women. The overall clinical pregnancy rate was 46.4% per started cycle. A total of 12 (13.6%) patients developed OHSS. “Freeze-all” policy did not attenuate OHSS in four patients, and three of these patients developed OHSS despite 1,500 IU hCG was not administered. Conclusion: We conclude that OHSS may still occur with the use of a GnRH agonist trigger combined with low-dose hCG supplementation protocol in women with polycystic ovary syndrome (PCOS) or PCO morphology. Furthermore, we also conclude that “freeze-all” policy also will not completely eliminate OHSS development in high-risk women. J Clin Med Res. 2016;8(5):396-401 doi: http://dx.doi.org/10.14740/jocmr2500w |
Databáze: | OpenAIRE |
Externí odkaz: |